Answers are grounded in this paper and cite their sources.
Cytokine-dependent, drug-sensitive, p53 wild-type (WT) FL5.12 cells and the doxorubicin-resistant derivative line (FL/Doxo) were used to determine the roles of the mechanisms by which p53 could alter Ying Yang 1 (YY1) transcription factor expression in early hematopoietic precursor cells. Drug resistance was associated with decreased p53 induction after doxorubicin treatment, which was caused by a higher level of proteosomal degradation of p53 and also resulted in a lower level of YY1 expression. Insertion of a dominant negative p53 gene further increased the resistance of the cells to chemotherapeutic drugs and also resulted in low levels of YY1 expression. Thus, in our system we could examine the effects of p53 and chemotherapeutic drugs on YY1 expression in a series of cells that were all derived from the common parental cell line. Doxorubicin increased the expression of the YY1 protein more in the parental cells, which have higher levels of WT p53, than in the doxorubicin-resistant cells. Thus, in our system of early hematopoietic cells YY1 expression was associated with functional p53 activity. In summary, our studies indicate that regulating YY1 activity may be a potential approach to regulate drug resistance.
No takes yet. Share an insight, caveat, or question.
McCubrey et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: